AnHorn Medicines Completes $10 Million Series A Financing to Advance Small Molecule-based Protein Degradation Platform
AnHorn Medicines, a private biotechnology company focused on the development of precision medicines for degrading disease-causing proteins, announced today the successful completion of a $10 million Series A financing. This financing will enable AnHorn Medicines to expedite the growth of its pipeline, advance development of drug candidates, and enhance its platform capabilities to rationally design bi-functional degraders and molecular glues that target the known drivers of cancers and other diseases currently unaddressed by conventional methods.
The Series A financing was led by Taiwania Capital with participation from new investors included TaiAn Technologies, Industrial Technology Investment Corporation, Hong Tai Electric Industrial, Black Marble Capital Management, Mega Venture Capital and Sunplus Technology.
In addition to financial resources, this round of investment brings impressive experience and intellectual resources to AnHorn Medicines in the form of two new members of the Board of Directors:
Bryan Kao, Ph.D., Sr. Investment Manager, Taiwania Capital;
Jo Shen, Ph.D., Common Director;
Chu-Chiang Lin, Ph.D., President and Chief Executive Officer of AnHorn Medicines.
“We are pleased to have the support of this strong group of investors who share our vision and believe in our approach to expand the field of protein degradation into a broader array of diseases.” said Chu-Chiang Lin, Ph.D., CEO of AnHorn Medicines.
AnHorn Medicines has built a next-generation protein degradation platform with highly focused and scalable chemical libraries that target critical disease-causing proteins. The team comprise diverse specialties which consists of medicinal chemistry, structural biology, machine learning-based chemistry, and pharmacology.
About AnHorn Medicines
AnHorn Medicines is a biotechnology company developing a next-generation protein degradation platform that targets cellular disease-causing proteins. The company’s proprietary drug discovery platform provides a unique approach to rationally design bi-functional degrader and molecular glue to have differentiated drug profiles.
AnHorn Medicines was founded in 2020, headquarters in Taipei, Taiwan. The founder, Dr. Chu-Chiang Lin, has over 20 years solid experience in drug discovery and development. The drug discovery team consists of personnel in medicinal chemistry, structural biology, machine learning-based chemistry, and pharmacology.
Wendy Lin, MBA, Operations Manager